Phaseline

Companies › SkinJect

SkinJect: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Doxorubicin-containing MNA
Topoisomerase II inhibitor delivered via dissolvable microneedle array
TOP2APhase 1Basal Cell Carcinoma–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04928222Doxorubicin-containing MNAPhase 1Basal Cell CarcinomaOncologyDec 2023

Targets

TOP2A (1)

Companies with the same targets

CNS Pharmaceuticals CSPC ZhongQi Pharmaceutical Technology ImmunityBio

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.